Topics

Low-grade gliomas | Treatment | Targeted therapy | Vorasidenib

Home > Publications > Topics > Low-grade gliomas > Treatment > Targeted terapy > Vorasidenib

Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304194. PMID: 37272516. Interventional study. ˍ

*Silvani A, Franceschi E.
A new era after a long wait: Vorasetinib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Tumori. 2024 Jan 2:3008916231217583. doi: 10.1177/03008916231217583. PMID: 38166539. Editorial. ˍ
RELATED ARTICLE
Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304194. PMID: 37272516. Interventional study. ˍ

Gatto L, Di Nunno V, Tosoni A, Bartolini S, Ranieri L, Franceschi E.
Vorasidenib in IDH1/2-mutant low-grade glioma: the grey zone of patient's selection.
Front Oncol. 2024 Jan 11;13:1339266. doi: 10.3389/fonc.2023.1339266. PMID: 38273856. Comment. ˍ
RELATED ARTICLE
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304194. PMID: 37272516. Interventional study. ˍ

Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti R.
IDH inhibition in gliomas: from preclinical models to clinical trials.
Nat Rev Neurol. 2024 May 17. doi: 10.1038/s41582-024-00967-7. PMID: 38760442. Review. ˍ

Lazarev S, Sindhu KK.
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?
Nat Rev Clin Oncol. 2024 Sep 12. doi: 10.1038/s41571-024-00944-5. PMID: 39266767. Perspective˰ ˍ

Malik H, Hudaib M, Rehman A.
Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.
J Pak Med Assoc. 2024 Sep 21;74(10):1912-1913. doi: 10.47391/JPMA.20428. PMID: 39407401. Perspective. ˍ

Tom MC, Nagpal S, Palmer JD, Breen WG, Pollom EL, Lehrer EJ, McGranahan TM, Shiue K, Chundury A, McClelland Iii S, Saeed H, Chang EL, Chiang VLS, Wang TJC, Knisely JPS, Chao ST, Milano MT.
An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors.
Radiother Oncol. 2024 Nov 16;202:110640. doi: 10.1016/j.radonc.2024.110640. PMID: 39557126. Recommendations˰ ˍ

Aduwo JY, McClelland S 3rd.
Censoring Analysis of the INvestigating VorasiDenib In GliOma (INDIGO) Phase III Randomized Controlled Trial.
Am J Clin Oncol. 2025 Feb 14. doi: 10.1097/COC.0000000000001175. PMID: 39950862. Editorial. ˍ
RELATED ARTICLE
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304194. PMID: 37272516. Interventional study. ˍ